Pages that link to "Q45848116"

The following pages link to Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220. (Q45848116):

Displaying 17 items.

• Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication (Q24671870) (← links)
• Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis (Q34076940) (← links)
• Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule (Q35488811) (← links)
• Control of viral disease: the development of Epstein-Barr virus vaccines (Q36464566) (← links)
• Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. (Q36873321) (← links)
• Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity (Q40059138) (← links)
• Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340 (Q40064225) (← links)
• Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones (Q40067251) (← links)
• Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo (Q40409896) (← links)
• Identification of a novel EBV-induced membrane glycoprotein of 43 kDa with H667 MAb (Q41704317) (← links)
• Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine (Q45149270) (← links)
• The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines (Q45750193) (← links)
• Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA. (Q45754295) (← links)
• In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340. (Q45839679) (← links)
• Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture. (Q53822207) (← links)
• Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes (Q92389017) (← links)
• A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection (Q96128238) (← links)